Cellebiologisk karakterisering av akutt myelogen leukemi (AML) celler.
- Prosjektnummer
- 911011
- Ansvarlig person
- Øystein Bruserud
- Institusjon
- Helse Bergen
- Prosjektkategori
- Forskningsprosjekt
- Helsekategori
- Blod og immunforsvar
- Forskningsaktivitet
Cellular immune responses in multiple myeloma patients with treatment-induced cytopenia early after high-dose chemotherapy and autologous peripheral blood stem cell transplantation.
Leuk Res 2004 May;28(5):461-8.
PMID: 15068899
How should clinical data be included in experimental studies of cancer immunology?
Cancer Immunol Immunother 2004 Aug;53(8):677-80. Epub 2004 apr 7
PMID: 15069584
Osteoblasts increase proliferation and release of pro-angiogenic interleukin 8 by native human acute myelogenous leukemia blasts.
Haematologica 2004 Apr;89(4):391-402.
PMID: 15075072
Better preservation of early hematopoietic progenitor cells when human peripheral blood progenitor cells are cryopreserved with 5 percent dimethylsulfoxide instead of 10 percent dimethylsulfoxide.
Transfusion 2004 May;44(5):785-9.
PMID: 15104663
Functional characterization of T lymphocytes derived from patients with acute myelogenous leukemia and chemotherapy-induced leukopenia.
Cancer Immunol Immunother 2004 Aug;53(8):740-7. Epub 2004 mai 5
PMID: 15133630
Characterization of ribosomal P autoantibodies in relation to cell destruction and autoimmune disease.
Scand J Immunol 2004 Jul-Aug;60(1-2):189-98.
PMID: 15238089
Single cell profiling of potentiated phospho-protein networks in cancer cells.
Cell 2004 Jul;118(2):217-28.
PMID: 15260991
In vitro effects of native human acute myelogenous leukemia blasts on fibroblasts and osteoblasts.
Int J Cancer 2004 Oct;111(6):858-67.
PMID: 15300797
Lipoteichoic acid derived from Enterococcus faecalis modulates the functional characteristics of both normal peripheral blood leukocytes and native human acute myelogenous leukemia blasts.
Eur J Haematol 2004 Nov;73(5):340-50.
PMID: 15458513
In vitro culture of human acute lymphoblastic leukemia (ALL) cells in serum-free media; a comparison of native ALL blasts, ALL cell lines and virus-transformed B cell lines.
Leuk Res 2003 May;27(5):455-64.
PMID: 12620297
Human acute lymphoblastic leukemia (ALL) blasts as accessory cells during T-cell activation: differences between patients in costimulatory capacity affect proliferative responsiveness and cytokine release by activated T cells.
Cancer Immunol Immunother 2003 Apr;52(4):215-25. Epub 2003 feb 15
PMID: 12669246
Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities.
Haematologica 2003 Apr;88(4):416-28.
PMID: 12681969
Effects of angiogenic regulators on in vitro proliferation and cytokine secretion by native human acute myelogenous leukemia blasts.
Eur J Haematol 2003 Jul;71(1):9-17.
PMID: 12801293
No differences in colony formation of peripheral blood stem cells frozen with 5% or 10% dimethyl sulfoxide.
J Hematother Stem Cell Res 2003 Jun;12(3):351-8.
PMID: 12857376
The angioregulatory phenotype of native human acute myelogenous leukemia cells: influence of karyotype, Flt3 abnormalities and differentiation status.
Eur J Haematol 2003 Sep;71(3):163-73.
PMID: 12930316
Modified fatty acids and their possible therapeutic targets in malignant diseases.
Expert Opin Ther Targets 2003 Oct;7(5):663-77.
PMID: 14498827
Characterization of clonogenic progenitors in autologous peripheral blood stem cell grafts: evaluation of a simple in vitro assay suitable for routine clinical use.
Hematology 2003 Oct;8(5):313-8.
PMID: 14530173
Functional evaluation of proliferative T cell responses in patients with severe T lymphopenia: characterization of optimal culture conditions and standardized activation signals for a simple whole blood assay.
J Hematother Stem Cell Res 2003 Oct;12(5):525-35.
PMID: 14594509
Risk of infections in hospitalized patients receiving intensive chemotherapy for hematologic malignancies. Immunological charact
- Disputert:
- november 2004
- Hovedveileder:
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til Faglig rapportering, Helse Vest